| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Nutrition (S.R., E.R., F.H.), Harvard School of Public Health, Channing Laboratory
Department of Epidemiology (S.R., E.R., F.H.), Harvard School of Public Health, Channing Laboratory
Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School (E.R., F.H.), Boston, Massachusetts
University of Missouri, Research Reactor Center, Columbia Missouri (J.S.M.)
Address reprint requests to: Swapnil Rajpathak, MD, DrPH, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461. Email: srajpath{at}aecom.yu.edu
Objective: Selenium as a component of glutathione peroxidase may be beneficial in insulin resistance, hence potentially may modify the risk of diabetes and cardiovascular disease (CVD). The aim of this study is to evaluate the association between toenail selenium and CVD among men with diabetes.
Methods: We performed cross-sectional and nested case-control analyses within the Health Professionals Follow-up Study, a cohort of men aged 40 to 75 years in 1986. The cross-sectional analysis compared healthy controls (n = 361) to men with diabetes only (n = 688), and men with prevalent diabetes and CVD (n = 198). The nested case-control study included 202 diabetic men who developed incident CVD during follow-up and 361 matched controls.
Results: After controlling for potential confounders, the odds ratio (OR) for prevalent diabetes was 0.43 (95% CI: 0.28, 0.64; p-trend <0.001) for the highest compared to the lowest quartile of selenium. Comparison between diabetic men with CVD and healthy controls yielded an OR of 0.86 (95% CI: 0.47, 1.56, p-trend = 0.37) between extreme quartiles. In the nested case-control analysis, the OR between extreme quartiles was 0.57 (95% CI: 0.29, 1.03; p-trend = 0.07), comparing diabetic men with incident CVD to healthy controls.
Conclusions: Our results suggest that levels of toenail selenium are lower among diabetic men with or without CVD than among healthy controls. However, this study could not distinguish between the effects of selenium on diabetes and those on CVD. Randomized clinical trials are needed to study potential benefits of selenium supplementation in the prevention and treatment of diabetes and CVD.
Key words: toenail selenium, diabetes, cardiovascular disease
This article has been cited by other articles:
|
|
 |
|
  M. G. Boosalis The Role of Selenium in Chronic Disease Nutr Clin Pract, April 1, 2008; 23(2): 152 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Stranges, J. R. Marshall, R. Natarajan, R. P. Donahue, M. Trevisan, G. F. Combs, F. P. Cappuccio, A. Ceriello, and M. E. Reid Effects of Long-Term Selenium Supplementation on the Incidence of Type 2 Diabetes: A Randomized Trial Ann Intern Med, August 21, 2007; 147(4): 217 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bleys, A. Navas-Acien, and E. Guallar Selenium and Diabetes: More Bad News for Supplements Ann Intern Med, August 21, 2007; 147(4): 271 - 272. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bleys, A. Navas-Acien, and E. Guallar Serum Selenium and Diabetes in U.S. Adults Diabetes Care, April 1, 2007; 30(4): 829 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Flores-Mateo, A. Navas-Acien, R. Pastor-Barriuso, and E. Guallar Selenium and coronary heart disease: a meta-analysis. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 762 - 773. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
